Introduction: The Challenge of Unexplained Hyperinsulinism

Congenital hyperinsulinism (HI) remains a complex diagnostic challenge for pediatric endocrinologists. While mutations in KATP channel genes often explain severe cases, many patients test negative for known genetic markers. Recent clinical research has now pinpointed HK1 intron 2 variants as a critical factor in these unexplained cases. These non-coding variants disrupt the normal silencing of hexokinase 1 in pancreatic beta cells, leading to inappropriate insulin secretion and persistent hypoglycemia.

Clinical Phenotypes of HK1 Intron 2 Variants

A multi-center study analyzed 281 individuals with genetics-negative HI and identified unique variants in approximately 6.4% of the cohort. The researchers observed that these variants lead to a remarkably variable clinical phenotype. For example, some infants presented on their first day of life, while others did not show symptoms until 21 months of age. Furthermore, the response to medical therapy varied significantly across the group. While nearly 40% of cases responded well to diazoxide, the majority remained unresponsive, with several requiring surgical pancreatectomy to manage their blood glucose levels.

Genetic Inheritance and Recurrence Risk

Understanding the inheritance patterns of these variants is vital for family counseling. The study found that roughly half of the identified HK1 intron 2 variants were de novo mutations. In contrast, the remaining cases were inherited from either maternal or paternal lines. Specifically, some parents carried the variant without exhibiting clinical symptoms themselves, suggesting variable penetrance. Therefore, screening for these intronic regions is essential not only for the patient’s clinical care but also for assessing the recurrence risk in future pregnancies.

Impact on Diagnostic Protocols

Historically, genetic testing for HI focused primarily on coding regions. However, this study underscores the necessity of including specific non-coding regions in diagnostic panels. By identifying these variants early, clinicians can better predict treatment outcomes and tailor management strategies. Moreover, recognizing the high prevalence of these variants in the genetics-negative population could significantly reduce the diagnostic odyssey for many families.

Frequently Asked Questions

How do HK1 intron 2 variants cause hypoglycemia?

HK1 is typically a \"disallowed gene\" in pancreatic beta cells, meaning its expression is suppressed to ensure glucose-regulated insulin release. Intron 2 variants disrupt this suppression, causing the gene to stay active and trigger insulin secretion even when blood glucose is low.

Are all children with these variants unresponsive to diazoxide?

No, the clinical response is variable. Research shows that about 39% of patients with these variants respond to diazoxide, while the rest may require alternative medical therapies or surgical intervention.

Is genetic testing for these variants available in India?

Yes, advanced genomic centers in India that offer whole-genome sequencing or targeted high-sensitivity panels can now detect these specific non-coding intronic variants.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Boodhansingh KE et al. Non-coding variants in intron 2 of HK1 associated with hyperinsulinism with variable clinical phenotype. J Clin Endocrinol Metab. 2026 Mar 10. doi: undefined. PMID: 41810512.

2. Wakeling MN, et al. Non-coding variants disrupting a tissue-specific regulatory element in HK1 cause congenital hyperinsulinism. Nat Genet. 2022 Nov;54(11):1615-1620.

3. Rosenfeld E, et al. Non-coding Variants in HK1 Account for 5% of Cases of Congenital Hyperinsulinism Without an Identified Genetic Cause. ESPE Abstracts. 2023;96:FC1.2.